The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
The excel stent: a good DES, but can we really stop clopidogrel after 6 months?
复制标题
excel支架：很好的DES，但6个月后我们真的能停止氯吡格雷吗？
DOI：
10.1016/j.jcin.2009.01.005
复制
发表时间：
2009
期刊：
影响因子：
--
通讯作者：
J. Margolis
中科院分区：
文献类型：
--
作者：
J. Margolis
In their report of the CREATE (Multi-Center Registry of Excel Biodegradeable Polymer Drug-Eluting Stents) study in this issue of JACC: Cardiovascular Interventions, Han et al.(1) suggest that the Excel stent (JW Medical System, Weihai, China)—a sirolimus-eluting stent with biodegradable polymer—has equal or superior major adverse cardiac event (MACE) rates to presently available drug-eluting stents (DES). Because the biodegradable polymer precludes late stent thrombosis (LST), only 6 months of clopidogrel are required. This is a well-designed study performed in a scientific manner. The data are reported objectively, and the authors recognize the deficiencies of a registry. Upon first reading, the results are impressive. On closer inspection, it is necessary to ask what the study actually showed, and is there any solid evidence that Excel is superior to presently available DES?
